Collectively, these results indicate that mucosal healing and clinical remission in IBD patients may be strongly related to the immunomodulatory effects from blocking TNF-α, with improvements to the intestinal barrier function occurring as a secondary effects that synergistically improve the outcome. This evidence concerns the gene TNF and irritable bowel syndrome.